Prothena (NASDAQ: PRTA) Highlights TDP-43 CYTOPE ALS Preclinical Data on Pathology

MicroRNA-126 Expression as a Way to Prevent TDP-43 Aggregation in Amyotrophic Lateral Sclerosis

TDP-43 is one of a small number of proteins in the brain that can misfold or otherwise become altered in ways that allow toxic aggregates to form, or even encourage other molecules of the same protein to become dysfunctional in the same way. TDP-43 aggregation in later life is a relatively recent discovery, and has a neurodegenerative condition newly named for it, limbic-predominant age-related TDP-43 encephalopathy (LATE). It has also been foun…

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

TDP-43 CYTOPE® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular disease pathways Systemically-administered TDP-43 CYTOPE rapidly and efficiently distributed to the brain and periphery, internalized into the cytosol and significantly reduced intracellular TDP-43 pathology in an ALS mouse model [...] The post Prothe…

Prothena (NASDAQ: PRTA) Highlights TDP-43 CYTOPE ALS Preclinical Data on Pathology

Prothena’s TDP-43 CYTOPE program shows systemic delivery to brain and periphery, reducing pTDP-43 pathology and RNA dysregulation in ALS models.